BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baran B. Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. World J Hepatol 2015; 7(13): 1742-1754 [PMID: 26167247 DOI: 10.4254/wjh.v7.i13.1742] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Shi H, Han Z, Liu J, Xue J, Zhang S, Zhu Z, Xia J, Huang M. Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels. Med Sci Monit 2017;23:5230-6. [PMID: 29095799 DOI: 10.12659/msm.903382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
2 Raffetti E, Fattovich G, Donato F. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis. Liver Int. 2016;36:1239-1251. [PMID: 27062182 DOI: 10.1111/liv.13142] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 10.8] [Reference Citation Analysis]
3 Takeuchi F, Ikeda S, Tsukamoto Y, Iwasawa Y, Qihao C, Otakaki Y, Ryota O, Yao WL, Narita R, Makoto H, Watashi K, Wakita T, Takeuchi K, Chayama K, Kogure A, Kato H, Fujita T. Screening for inhibitor of episomal DNA identified dicumarol as a hepatitis B virus inhibitor. PLoS One 2019;14:e0212233. [PMID: 30779774 DOI: 10.1371/journal.pone.0212233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
4 Madeddu G, Ortu S, Garrucciu G, Maida I, Melis M, Muredda AA, Mura MS, Babudieri S. DNMT1 modulation in chronic hepatitis B patients and hypothetic influence on mitochondrial DNA methylation status during long-term nucleo(t)side analogs therapy. J Med Virol 2017;89:1208-14. [PMID: 27922198 DOI: 10.1002/jmv.24742] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
5 Li ZQ, Hu CL, Yu P, Gu XY, Zhang JJ, Li H, Zhang HY, Lv J, Liu YM, Zeng QL, Yan JY, Yu ZJ, Zhang Y. The development of hepatocarcinoma after long-term antivirus treatment of Chinese patients with chronic hepatitis B virus infection: Incidence, long-term outcomes and predictive factors. Clin Res Hepatol Gastroenterol. 2017;41:311-318. [PMID: 28237828 DOI: 10.1016/j.clinre.2016.11.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
6 Ding Y, Lou J, Chen H, Li X, Wu M, Li C, Liu J, Liu C, Li Q, Zhang H, Niu J. Tolerability, pharmacokinetics and antiviral activity of rHSA/IFNα2a for the treatment of chronic hepatitis B infection. Br J Clin Pharmacol 2017;83:1056-71. [PMID: 27862178 DOI: 10.1111/bcp.13184] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
7 Qiu J, Xu B, Gong Q, Pan W, Liu C, Huang Z, Gu X, Liang G. Synthesis and Biological Evaluation of Matijin-Su Derivatives as Potential Antihepatitis B Virus and Anticancer Agents. Chem Biodivers 2016;13:1584-92. [PMID: 27451105 DOI: 10.1002/cbdv.201600113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Brar TS, Hilgenfeldt E, Soldevila-pico C. Etiology and Pathogenesis of Hepatocellular Carcinoma. In: Liu C, editor. Precision Molecular Pathology of Liver Cancer. Cham: Springer International Publishing; 2018. pp. 1-15. [DOI: 10.1007/978-3-319-68082-8_1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
9 Koike K, Suyama K, Ito H, Itoh H, Sugiura W. Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naïve chronic hepatitis B patients: Non-inferiority of TDF to ETV in CHB. Hepatol Res 2018;48:59-68. [DOI: 10.1111/hepr.12902] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 7.2] [Reference Citation Analysis]
10 Frager SZ, Schwartz JM. Hepatocellular carcinoma: epidemiology, screening, and assessment of hepatic reserve. Curr Oncol 2020;27:S138-43. [PMID: 33343207 DOI: 10.3747/co.27.7181] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
11 Ye YA, Li XK, Zhou DQ, Chi XL, Li Q, Wang L, Lu BJ, Mao DW, Wu QK, Wang XB, Zhang MX, Xue JD, Li Y, Lu W, Guo JC, Jiang F, Zhang XW, Du HB, Yang XZ, Guo H, Gan DN, Li ZG. Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B: Study Protocol for a Multi-Center, Double-Blind Randomized-Controlled Trial. Chin J Integr Med 2018;24:653-60. [PMID: 30209792 DOI: 10.1007/s11655-018-3011-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
12 Wang B, Agarwal K, Joshi D. Management of chronic hepatitis B before and after liver transplantation. Frontline Gastroenterol 2018;9:79-84. [PMID: 29484165 DOI: 10.1136/flgastro-2016-100768] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
13 Hwang S, Song GW, Jung DH, Yoon YI, Yoo HJ, Tak E. High-dose tenofovir is not effective in suppressing hepatitis B virus replication in patients with hepatocellular carcinoma progression: a preliminary result. Korean J Hepatobiliary Pancreat Surg 2016;20:8-11. [PMID: 26925144 DOI: 10.14701/kjhbps.2016.20.1.8] [Reference Citation Analysis]